Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Launched by MASSACHUSETTS GENERAL HOSPITAL · Oct 9, 2013

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to detect cancer cells in the blood of men who have localized prostate cancer and are scheduled to have surgery to remove their prostate. Researchers believe that tiny cancer cells called circulating tumor cells (CTCs) can provide important information about the tumor's status and how well it is responding to treatment. By measuring the number of these cells in the blood before and after surgery, the study aims to see if this method can help doctors better understand the cancer and improve patient care.

To participate in this trial, you need to be a male aged 18 or older with a confirmed diagnosis of non-metastatic prostate cancer, meaning the cancer has not spread to other parts of the body. You should also be planning to have a radical prostatectomy at Massachusetts General Hospital. Participants should not have had any prior treatments for prostate cancer, like radiation or hormone therapy. If you join the study, you will provide blood samples at different times around your surgery to help researchers gather data about the CTCs. This trial is currently recruiting participants, so you might have the opportunity to contribute to important research that could benefit future patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male
• • 18 years of age or older
• • Pathologically confirmed diagnosis of prostate adenocarcinoma
• • Non-metastatic prostate cancer
• • Planned radical prostatectomy at Massachusetts General Hospital
• Exclusion Criteria:
• • Patients must not have received prior radiation therapy, hormone therapy, or other medical therapy for prostate cancer prior to prostatectomy. Post-prostatectomy therapy at the discretion of the patient's treating physician(s) is allowed.
• • Patients must not have metastatic prostate cancer
• • No prior or current diagnosis of epithelial malignancy, except for skin cancer (squamous cell carcinoma or basal cell carcinoma)